Zacks Investment Research downgraded shares of SANUWAVE Health (SNWV) from OUTPERFORM to NEUTRAL on January 30, 2013, with a target price of $1.30.
In May 2012 FDA gave the green-light to SNWV's proposed IDE Supplement and add'l clinical trial. With treatment boosts, the trial could show endpoint-hitting efficacy. Important to understand is that this is not a replacement trial but is instead a supplement in every sense of the word – this supplemental data will be in addition to and build on the already very strong and compelling initial trial data. Enrollment for supplemental trial now expected in Q1 2013. We remain big believers in dermaPACE and SNWV's management. If all goes well dermaPACE could be on the U.S. mrkt in 2015.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SANUWAVE Health (SNWV),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment